Long-term effects of ranibizumab on diabetic retinopathy severity and progression
MS Ip, A Domalpally, JJ Hopkins, P Wong… - Archives of …, 2012 - jamanetwork.com
Objective To evaluate effects of intravitreal ranibizumab on diabetic retinopathy (DR)
severity over time in 2 phase 3 clinical trials (RIDE, NCT00473382; RISE, NCT00473330) of
ranibizumab for diabetic macular edema. Methods Participants with diabetic macular edema
(n= 759) were randomized to monthly sham, 0.3-mg ranibizumab, or 0.5-mg ranibizumab
intravitreal injections. Macular laser was available per protocol-specified criteria. Fundus
photographs, taken at baseline and periodically, were graded by a central reading center; …
severity over time in 2 phase 3 clinical trials (RIDE, NCT00473382; RISE, NCT00473330) of
ranibizumab for diabetic macular edema. Methods Participants with diabetic macular edema
(n= 759) were randomized to monthly sham, 0.3-mg ranibizumab, or 0.5-mg ranibizumab
intravitreal injections. Macular laser was available per protocol-specified criteria. Fundus
photographs, taken at baseline and periodically, were graded by a central reading center; …